AZN,ENDP,GSK -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
    Zacks2 hours ago

    AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan

    AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.

  • Inside Novartis’s 4Q17 Earnings: Analyst Estimates
    Market Realist4 hours ago

    Inside Novartis’s 4Q17 Earnings: Analyst Estimates

    Novartis’s 4Q17 Earnings: Behind the ExpectationsA look at Novartis’s earnings

  • Markit4 hours ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Johnson & Johnson’s Consumer Segment: 4Q17 Estimates
    Market Realist5 hours ago

    Johnson & Johnson’s Consumer Segment: 4Q17 Estimates

    Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.

  • Better Buy: GlaxoSmithKline plc vs. Eli Lilly
    Motley Foolyesterday

    Better Buy: GlaxoSmithKline plc vs. Eli Lilly

    Both big pharma stocks have growth drivers. But both also come with baggage.

  • Top Picks For Pharma And Biotech Dividend Rockstars
    Simply Wall St.2 days ago

    Top Picks For Pharma And Biotech Dividend Rockstars

    When investors think of dividend stocks, pharmaceutical and biotech companies aren’t usually front of mind. Even though drugs are relatively non-cyclical, these stocks are subjected to high regulatory risks. Yet,Read More...

  • Reuters3 days ago

    Delaware sues opioid manufacturers, distributors over epidemic

    Delaware on Friday became the latest state to file a lawsuit accusing corporations of helping fuel the national opioid epidemic, suing a wide range of companies involved in making, distributing and selling prescription painkillers. The lawsuit, filed by Delaware Attorney General Matt Denn in a state court, targeted drugmakers Purdue Pharma LP and Endo International Plc along with several wholesale drug distributors and the retailers CVS Health Corp and Walgreens Boots Alliance Inc. The lawsuit accused Purdue and Endo of engaging in a massive marketing campaign aimed at concealing the risks of using opioids to treat chronic pain in order to overcome a medical consensus that using the drugs for that purpose was unsafe.

  • Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb
    Market Realist3 days ago

    Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb

    What Could Drive Bristol-Myers Squibb in 2018?

  • Cancer Space Update: Label Expansions, Data Readouts in Focus
    Zacks3 days ago

    Cancer Space Update: Label Expansions, Data Readouts in Focus

    This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.

  • Amgen’s Aimovig is Expected to Witness Steady Growth in 2018
    Market Realist3 days ago

    Amgen’s Aimovig is Expected to Witness Steady Growth in 2018

    How Is Amgen Positioned for 2018?

  • Reuters4 days ago

    At AstraZeneca, fewer drug projects bring big productivity jump

    A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca (AZN.L), based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organisation and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot.

  • Reuters4 days ago

    At AstraZeneca, fewer drug projects bring big productivity jump

    A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca (AZN.L), based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organization and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot.

  • TheStreet.com4 days ago

    Why Hospitals Shouldn't Terrify Generic Drug Companies

    A group of hospital systems led by Intermountain Healthcare said Jan. 18 they are planning to form a not-for-profit generic drug firm to address drug shortages and high costs.

  • Why This Biotech Stock Could Outperform Expectations In Lung Cancer
    Investor's Business Daily4 days ago

    Why This Biotech Stock Could Outperform Expectations In Lung Cancer

    AstraZeneca could bring in $3.8 billion in peak sales of immuno-oncology drug Imfinzi, an analyst said Thursday.

  • J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
    Zacks4 days ago

    J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

    Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

  • See what the IHS Markit Score report has to say about Endo International PLC.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Benzinga5 days ago

    Pieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says

    Shares of the clinical-stage biotech company  Pieris Pharmaceuticals Inc (NASDAQ: PIRS ) are poised to outperform over the coming 12 to 18 months, according to William Blair.  The Analyst William Blair ...

  • SmarterAnalyst5 days ago

    Here’s Why Neurometrix Inc Rose as Much as 60% Today

    Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning after the healthcare company announced a new collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK), involving Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Specifically, GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. Neurometrix will receive a payment of $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones. Investors will need to wait to see more precise details, but for a penny stock such as Neurometrix, this is pretty amazing no matter the exact dollar amount.

  • Reuters5 days ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline (GSK.L) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Five years ago, forecasters predicted annual African drug sales would reach $45 billion by 2020.

  • Reuters5 days ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region.

  • Nektar Boasts Strong Pipeline, Competition Remains a Woe
    Zacks5 days ago

    Nektar Boasts Strong Pipeline, Competition Remains a Woe

    Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

  • Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018
    Market Realist5 days ago

    Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018

    How Is Amgen Positioned for 2018?

  • MarketWatch5 days ago

    NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell

    Shares of NeuroMetrix Inc. rocketed 78% toward a 7-month high in active premarket trade Wednesday, after chronic pain treatments company announced a collaboration with GlaxoSmithLine PLC involving NeuroMetrix's ...

  • Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa
    Bloomberg5 days ago

    Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa

    GlaxoSmithKline Plc is cutting jobs in Africa and restructuring in more than two dozen countries across the continent, reversing earlier expansion efforts as new Chief Executive Emma Walmsley tries to ...

  • Dow's Merck Does An About-Face, Releases Cancer Trial Results
    Investor's Business Daily6 days ago

    Dow's Merck Does An About-Face, Releases Cancer Trial Results

    Merck surged to a three-month high Tuesday on strong results for its immuno-oncology and chemotherapy regimen in lung cancer.